SanaCurrents

/SanaCurrents

ADMA Biologics (NASDAQ:ADMA) December Catalyst: PDUFA for BIVIGAM

SanaCurrents assigns a pivotal sentiment the FDA will approve the [...]

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – 3Q 2019 catalyst, CBD treatment for Fragile X

3Q ‘19 catalyst, CBD treatment for Fragile X SanaCurrents is [...]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – December Catalyst, Lymphoma Phase IIb Trial

December catalyst, lymphoma phase IIb trial SanaCurrents assigns a pivotal [...]

Update on Eidos Therapeutics after Positive Phase II Results

Eidos Therapeutics, Inc. (NASDAQ:EIDX) shares are up as much as [...]

Galmed (GLMD) – November Catalyst: Aramchol

November Catalyst: Aramchol SanaCurrents forecasts an advantageous probability Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) [...]

Eidos Therapeutics (EIDX) – 4Q Catalyst: AG10 phase II data

4Q Catalyst: AG10 phase II data Based on its analytics [...]

ARMO Biosciences (ARMO) – SanaCurrents Case Study

ARMO Biosciences (ARMO) listed in January 2018 at $17 per [...]

Top